C.Beheshti ZavarehR.AnglinJ
These agents include agonists targeting costimulatory receptors such as CD137 (e.g., urelumab or anti-4-1BB/PD-L1 bispecific antibody) [347,348,349,350], CD20 (e.g., rituximab) [351, 352], CD27 (e.g., varlilumab, augments T-cell proliferation) [353, 354], OX40/OX40 ligand [355], CD80 [356], as well as agents like CD40 agonists (e.g., sotigalimab) that enhance antigen presentation by activating DCs and macrophages, which improves antigen presentation and primes a more robust T-cell response [357, 358]
Une partie du glutathion ingr est dgrade lors de la digestion, ce qui limite sa biodisponibilit
In this situation, a health care professional will take a small sample of blood
It is important to note that Hydroxocobalamin 20 mg/ml Injection Solution should not be used in patients with known hypersensitivity to hydroxocobalamin or any of the other ingredients in the solution